BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 2, 2025
See today's BioWorld
Home
» China's slowdown could have an impact on biopharma companies
To read the full story,
subscribe
or
sign in
.
China's slowdown could have an impact on biopharma companies
Dec. 31, 2014
By
Kristine Yang
No Comments
HONG KONG – The health care industry in China could go through a period of flux over the next year as it responds to widespread changes to the country's economy.
BioWorld